Automated insulin delivery

Automated insulin delivery has been studied in 4 papers since 2025: 2 trials in people, 2 reviews; 2 in the past year. The newest paper, Jul 30, 2026: “Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study”.

Intervention

4 papers study it4 findingsUpdated

See all 4 papers on automated insulin delivery

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country.

“AHCL therapy was associated with a lower HFS-II score than standard treatment (adjusted mean difference -18.9; 95% CI: -32.4 to -5.4; nominal p = 0.008)”
Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre StudyDiabetes, obesity & metabolism2026doi:10.1111/dom.71170

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • Funders: Medtronic and 3 more
  • 4 of 4 findings with company ties
  • Human trial2

Studies in people

1 study gave automated insulin delivery to people and measured what changed.

What changedDesignPeopleSource

down: Decreases Hypoglycemia Fear Survey-IIadjusted mean difference -18.9; 95% CI: -32.4 to -5.4

up: Increases 6-minute walk distance92.6 m; 95% CI: 36.8 to 148.3

down: Decreases Timed Up-and-Go-2.27 s; 95% CI: -4.28 to -0.27

Randomized trial12 months29 peopleBoth≥ 65 yearsOlder adults; in adults aged ≥ 65 years with type 1 diabetesDiabetes, obesity & metabolism, Jul 30, 2026

What did studies of automated insulin delivery find?

4

Studies of automated insulin delivery measured 4 outcomes, among them gait speed, Timed Up-and-Go and 6-minute walk distance.

Gait speed

no changein humans1

1 study
  1. Automated insulin delivery showed no clear effect on gait speed in adults aged ≥ 65 years with type 1 diabetes, sex-adjusted (0.27 m/s; 95% CI: -0.05 to 0.59).

    “not for gait speed (0.27 m/s; 95% CI: -0.05 to 0.59; p = 0.099)”

    Human trialin adults aged ≥ 65 years with type 1 diabetes, sex-adjustedMiniMed 780G system12 monthsn = 29

    Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study

    Diabetes, obesity & metabolism

More on Gait speed

Timed Up-and-Go

downin humans1

1 study
  1. Automated insulin delivery decreases Timed Up-and-Go in adults aged ≥ 65 years with type 1 diabetes, sex-adjusted (-2.27 s; 95% CI: -4.28 to -0.27).

    “Timed Up and Go performance (-2.27 s; 95% CI: -4.28 to -0.27; p = 0.028)”

    Human trialin adults aged ≥ 65 years with type 1 diabetes, sex-adjustedMiniMed 780G system12 monthsn = 29

    Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study

    Diabetes, obesity & metabolism

More on Timed Up-and-Go

6-minute walk distance

upin humans1

1 study
  1. Automated insulin delivery increases 6-minute walk distance in adults aged ≥ 65 years with type 1 diabetes, sex-adjusted (92.6 m; 95% CI: 36.8 to 148.3).

    “between-group differences remained statistically significant for 6-min walk distance (92.6 m; 95% CI: 36.8 to 148.3; p = 0.002)”

    Human trialin adults aged ≥ 65 years with type 1 diabetes, sex-adjustedMiniMed 780G system12 monthsn = 29

    Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study

    Diabetes, obesity & metabolism

More on 6-minute walk distance

Hypoglycemia Fear Survey-II

downin humans1

1 study
  1. Automated insulin delivery decreases Hypoglycemia Fear Survey-II in adults aged ≥ 65 years with type 1 diabetes (adjusted mean difference -18.9; 95% CI: -32.4 to -5.4).

    “AHCL therapy was associated with a lower HFS-II score than standard treatment (adjusted mean difference -18.9; 95% CI: -32.4 to -5.4; nominal p = 0.008)”

    Human trialin adults aged ≥ 65 years with type 1 diabetesMiniMed 780G system12 monthsn = 29

    Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed-Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single-Centre Study

    Diabetes, obesity & metabolism

More on Hypoglycemia Fear Survey-II

Funding

3 grants since 2021

National Heart, Lung, and Blood Institute$931KNational Institute of Diabetes and Digestive and Kidney Diseases$1.3M

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 1Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months